

(19)



(11)

EP 2 222 710 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:

12.10.2016 Bulletin 2016/41

(45) Date of publication and mention of the grant of the patent:

27.07.2016 Bulletin 2016/30

(21) Application number: **08864495.0**

(22) Date of filing: **23.12.2008**

(51) Int Cl.:

C07K 19/00 <small>(2006.01)</small>	A61K 39/00 <small>(2006.01)</small>
A61K 39/155 <small>(2006.01)</small>	A61K 39/295 <small>(2006.01)</small>
A61K 9/107 <small>(2006.01)</small>	A61K 9/127 <small>(2006.01)</small>
A61P 31/14 <small>(2006.01)</small>	A61P 37/04 <small>(2006.01)</small>
C07K 14/135 <small>(2006.01)</small>	C12N 15/45 <small>(2006.01)</small>
C12N 15/62 <small>(2006.01)</small>	C07K 14/005 <small>(2006.01)</small>

(86) International application number:

PCT/CA2008/002277

(87) International publication number:

WO 2009/079796 (02.07.2009 Gazette 2009/27)

(54) **RECOMBINANT RSV ANTIGENS**

REKOMBINANTE RSV-ANTIGENE

ANTIGÈNES RECOMBINANTS DU RSV

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

Designated Extension States:

AL BA MK RS

(30) Priority: **24.12.2007 US 16524 P**

27.05.2008 US 56206 P

(43) Date of publication of application:

01.09.2010 Bulletin 2010/35

(60) Divisional application:

16180926.4

(73) Proprietors:

- **ID Biomedical Corporation of Quebec Quebec G1P 4R8 (CA)**
- **GlaxoSmithKline Biologicals S.A. 1330 Rixensart (BE)**

(72) Inventors:

- **BAUDOUX, Jean-Pierre B-1330 Rixensart (BE)**

- **BLAIS, Normand Laval Québec H6V 3S8 (CA)**
- **RHEAULT, Patrick Laval Québec H7V 3S8 (CA)**
- **RUELLE, Jean-Louis B-1330 Rixensart (BE)**

(74) Representative: **Thornley, Rachel Mary et al**

GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)

(56) References cited:

WO-A2-2008/114149 WO-A2-2008/154456

- **YIN HSIEN-SHENG ET AL: "Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 439, no. 7072, 1 January 2006 (2006-01-01), pages 38-44, XP002503490, ISSN: 0028-0836, DOI: 10.1038/NATURE04322**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 222 710 B8

- BEGONA RUIZ-ARGUELLO M ET AL: "Effect of Proteolytic Processing at Two Distinct Sites on Shape and Aggregation of an Anchorless Fusion Protein of Human Respiratory Syncytial Virus and Fate of the Intervening Segment", *VIROLOGY*, ACADEMIC PRESS, ORLANDO, US, vol. 298, no. 2, 5 July 2002 (2002-07-05), pages 317-326, XP004469494, ISSN: 0042-6822, DOI: 10.1006/VIRO.2002.1497
- VAN DRUNEN LITTEL-VAN DEN HURK S ET AL: "Immunopathology of RSV infection: prospects for developing vaccines without this complication", *REVIEWS IN MEDICAL VIROLOGY*, CHICHESTER, GB, vol. 17, no. 1, 1 January 2007 (2007-01-01), pages 5-34, XP002510797, ISSN: 1052-9276, DOI: 10.1002/RMV.518 [retrieved on 2006-09-27]
- PRINCE GREGORY A ET AL: "Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats", *JOURNAL OF VIROLOGY*, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 22, 1 November 2000 (2000-11-01), pages 10287-10292, XP002676837, ISSN: 0022-538X
- SINGH ET AL: "Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model", *VACCINE*, ELSEVIER LTD, GB, vol. 25, no. 33, 24 July 2007 (2007-07-24), pages 6211-6223, XP022168621, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2007.05.068
- TERNETTE ET AL: "Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus", *VACCINE*, ELSEVIER LTD, GB, vol. 25, no. 41, 27 September 2007 (2007-09-27), pages 7271-7279, XP022276681, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2007.07.025
- CALDER L J ET AL: "Electron Microscopy of the Human Respiratory Syncytial Virus Fusion Protein and Complexes That It Forms with Monoclonal Antibodies", *VIROLOGY*, ACADEMIC PRESS, ORLANDO, US, vol. 271, no. 1, 25 May 2000 (2000-05-25), pages 122-131, XP004436029, ISSN: 0042-6822, DOI: 10.1006/VIRO.2000.0279
- ULBRANDT NANCY D ET AL: "Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus", *JOURNAL OF GENERAL VIROLOGY*, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 89, no. Part 12, 1 December 2008 (2008-12-01), pages 3113-3118, XP002604581, ISSN: 0022-1317, DOI: 10.1099/VIR.0.2008/005199-0
- MARTIN, D. ET AL.: 'Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity.' *JOURNAL OF GENERAL VIROLOGY* vol. 87, no. 6, June 2006, pages 1649 - 1658, XP002600413
- GONZALEZ-REYES, L. ET AL.: 'Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion.' *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE USA* vol. 98, no. 17, 14 August 2001, pages 9859 - 9864, XP008136810
- YIN, H.-S. ET AL.: 'Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation.' *NATURE* vol. 439, no. 7072, 05 January 2006, pages 38 - 44, XP002600415
- SCHMIDT, A. C. ET AL.: 'Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.' *JOURNAL OF VIROLOGY* vol. 76, no. 3, February 2002, pages 1089 - 1099, XP002978183
- HUANG Y. ET AL.: 'Modulation of protective immunity, eosinophilia, and cytokine responses by selective mutagenesis of a recombinant G protein vaccine against respiratory syncytial virus.' *JOURNAL OF VIROLOGY* vol. 79, no. 7, April 2005, pages 4527 - 4532, XP002600416
- TANG, R. S. ET AL.: 'Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys.' *JOURNAL OF VIROLOGY* vol. 78, no. 20, October 2004, pages 11198 - 11207, XP002600417
- VALARCHER, J.-F. ET AL.: 'Bovine respiratory syncytial virus lacking the virokinin or with a mutation in furin cleavage site RA(R/K)R109 induces less pulmonary inflammation without impeding the induction of protective immunity in calves.' *JOURNAL OF GENERAL VIROLOGY* vol. 87, no. 6, June 2006, pages 1659 - 1667, XP008136764